Abstract
Therapeutic antibodies have gained prominence in recent years due to their precision in targeting specific diseases. As these molecules become increasingly essential in modern medicine, comprehensive data tracking and analysis are critical for advancing research and ensuring successful clinical outcomes. YAbS, The Antibody Society’s Antibody Therapeutics Database, serves as a vital resource for monitoring the development and clinical progress of therapeutic antibodies. The database catalogues detailed information on over 2,900 commercially sponsored investigational antibody candidates that have entered clinical study since 2000, as well as all approved antibody therapeutics. Data for the late-stage clinical pipeline and antibody therapeutics in regulatory review or approved (over 450 molecules) are openly accessible (https://db.antibodysociety.org). Antibody-related information includes molecular format, targeted antigen, current development status, indications studied, and the clinical development timeline of the antibodies, as well as the geographical region of company sponsors. Furthermore, the database supports in-depth industry trends analysis, facilitating the identification of innovative developments and the assessment of success rates within the field. This resource is continually updated and refined, providing invaluable insights to researchers, clinicians, and industry professionals engaged in antibody therapeutics development.
Competing Interest Statement
SC and JMR are employed by The Antibody Society, Inc., a non-profit trade association funded by corporate sponsors that develop antibody therapeutics or provide services to companies that develop antibody therapeutics. JMR is also Editor-in-Chief of mAbs, a biomedical journal focused on topics relevant to antibody therapeutics development. V.G. declares advisory board positions in aiNET GmbH, Enpicom B.V, Absci, Omniscope, and Diagonal Therapeutics. V.G. is a consultant for Adaptyv Biosystems, Specifica Inc, Roche/Genentech, immunai, Proteinea, LabGenius, and FairJourney Biologics.
Footnotes
Puneet Rawat: Email puneet.rawat{at}medisin.uio.no; Victor Greiff: Email victor.greiff{at}medisin.uio.no; Silvia Crescioli: Email silvia.crescioli{at}antibodysociety.org; Janice Reichert: Email janice.reichert{at}antibodysociety.org; Prabakaran Ram: Email prabakaran{at}emory.edu; Divya Sharma: Email bt19d752{at}smail.iitm.ac.in;
Abbreviations
- Ab
- antibody
- ADC
- antibody-drug conjugate
- BLA
- biologics license application
- Fab
- antigen-binding fragment
- Fc
- crystallizable fragment
- FDA
- US Food and Drug Administration
- FIH
- first-in-human
- HER2
- human epidermal growth factor-2
- Ig
- immunoglobulin
- IND
- investigational new drug
- INN
- international non-proprietary name
- mAb
- monoclonal antibody
